Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12000493 | 0.83 | PTGS1 (0.60) | PTGS1SMN1; SMN2LMNAPOLBGABRA5 | |
| SCHEMBL2568217 | 0.83 | PTGS1 (0.73) | PTGS1SMN1; SMN2LMNAPOLBGABRA5 | |
| SCHEMBL17873985 | 0.82 | KMT2A (0.45) | PTGS1SMN1; SMN2LMNAALDH1A1MEN1 | |
| SCHEMBL2570531 | 0.82 | PTGS1 (0.67) | PTGS1SMN1; SMN2LMNAPOLBALDH1A1 | |
| SCHEMBL1805305 | 0.81 | PTGS1 (0.55) | PTGS1SMN1; SMN2LMNAPOLBGABRA5 | |
| SCHEMBL2570844 | 0.81 | PTGS1 (0.55) | PTGS1SMN1; SMN2LMNAPOLBGABRA5 | |
| SCHEMBL2565750 | 0.79 | PTGS1 (0.68) | PTGS1SMN1; SMN2LMNAPOLBGABRA5 | |
| SCHEMBL13349506 | 0.79 | PTGS1 (0.56) | PTGS1SMN1; SMN2LMNAPOLBGABRA5 | |
| SCHEMBL2565828 | 0.79 | PTGS1 (0.56) | PTGS1SMN1; SMN2LMNAPOLBGABRA5 | |
| SCHEMBL2570798 | 0.79 | PTGS1 (0.71) | PTGS1SMN1; SMN2LMNAPOLBGABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240139158-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS INC (US) | 2024-05-02 | — | — | US | disclosed |
| EP-3237411-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3237411-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220175735-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS INC (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220175735-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS INC (US) | 2022-06-09 | — | — | US | disclosed |
| CN-107207487-B | Compounds, compositions and methods for increasing CFTR activity | 蛋白质平衡治疗股份有限公司 | 2021-12-28 | — | — | CN | disclosed |
| US-11083709-B2 | Compounds, compositions, and methods of increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-11083709-B2 | Compounds, compositions, and methods of increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20200360348-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2020-11-19 | — | — | US | disclosed |
| US-20200360348-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2020-11-19 | — | — | US | disclosed |
| EP-3325474-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | Proteostasis Therapeutics, Inc. (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20170369480-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2017-12-28 | — | — | US | disclosed |
| US-20170369480-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2017-12-28 | — | — | US | disclosed |
| EP-3237411-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | Proteostasis Therapeutics, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| WO-2017112853-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017112853-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017019589-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-02-02 | — | — | WO | disclosed |
| WO-2017019589-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-02-02 | — | — | WO | disclosed |
| WO-2016105485-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016105485-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139158-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | SMPD1, ELANE, SMPD2 | PTGS1 261/4885SMN1; SMN2 1913/4885LMNA 3043/4885 |
| US-20200360348-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF INCREASING CFTR ACTIVITY | CFTR, ABCB4, SCNN1B | PTGS1 1492/4885SMN1; SMN2 3701/4885LMNA 2454/4885 |
| US-20170369480-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | CFTR, SCNN1B, SCNN1G | PTGS1 2402/4885SMN1; SMN2 4744/4885LMNA 2025/4885 |
| US-11083709-B2 | Compounds, compositions, and methods of increasing CFTR activity | CFTR, ABCB4, SCNN1B | PTGS1 1492/4885SMN1; SMN2 3701/4885LMNA 2454/4885 |
| US-20220175735-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | SMPD1, ELANE, SMPD2 | PTGS1 261/4885SMN1; SMN2 1913/4885LMNA 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.